Alembic Pharmaceuticals reported its consolidated Q3 results with steady operational growth, even as net profit declined on account of an exceptional expense linked to new labour codes.
For the December quarter, Alembic Pharma’s consolidated revenue rose 10.8% year-on-year to Rs 1,876 crore, compared with Rs 1,693 crore in the same period last year. The topline growth reflects stable performance across key business segments and continued traction in core markets.
Operating performance remained resilient during the quarter. EBITDA increased 12.8% year-on-year to Rs 294 crore from Rs 260 crore a year ago. EBITDA margin improved marginally to 15.6% versus 15.4% in the corresponding quarter last year, indicating controlled costs and operational efficiency despite industry-wide pressures.
However, consolidated net profit declined 3.9% year-on-year to Rs 133 crore, compared with Rs 138 crore in Q3 of the previous financial year. The company attributed the decline primarily to a one-time loss of Rs 42.2 crore incurred due to the implementation of labour codes